RVX
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, RVX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +170% compared to the S&P TSX Composite Index (Canada)'s +19% growth.
Stocks Performance
RVX vs S&P TSX Composite Index (Canada)
Performance Gap
RVX vs S&P TSX Composite Index (Canada)
Performance By Year
RVX vs S&P TSX Composite Index (Canada)
Resverlogix Corp
Glance View
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
